Pensionfund Sabic raised its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 58.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 32,500 shares of the company’s stock after acquiring an additional 12,000 shares during the quarter. Merck & Co., Inc. makes up 0.8% of Pensionfund Sabic’s holdings, making the stock its 27th largest holding. Pensionfund Sabic’s holdings in Merck & Co., Inc. were worth $3,233,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in MRK. State Street Corp boosted its position in Merck & Co., Inc. by 1.3% in the 3rd quarter. State Street Corp now owns 119,026,412 shares of the company’s stock worth $13,606,360,000 after purchasing an additional 1,536,474 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Merck & Co., Inc. by 4.6% in the third quarter. Wellington Management Group LLP now owns 75,809,383 shares of the company’s stock valued at $8,608,914,000 after acquiring an additional 3,327,404 shares during the last quarter. Geode Capital Management LLC lifted its position in Merck & Co., Inc. by 3.7% in the third quarter. Geode Capital Management LLC now owns 59,155,004 shares of the company’s stock valued at $6,696,060,000 after buying an additional 2,134,296 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Merck & Co., Inc. by 2.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 18,807,293 shares of the company’s stock valued at $2,135,785,000 after purchasing an additional 514,060 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Merck & Co., Inc. by 1.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,756,021 shares of the company’s stock valued at $2,016,374,000 after acquiring an additional 309,656 shares during the period. 76.07% of the stock is currently owned by institutional investors.
Merck & Co., Inc. Price Performance
Merck & Co., Inc. stock traded down $0.23 during midday trading on Monday, hitting $98.91. 949,505 shares of the company’s stock were exchanged, compared to its average volume of 4,227,606. The stock has a 50-day moving average price of $100.53 and a two-hundred day moving average price of $111.68. The company has a market cap of $250.21 billion, a P/E ratio of 20.74, a PEG ratio of 1.47 and a beta of 0.39. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.15 and a current ratio of 1.36. Merck & Co., Inc. has a 52-week low of $94.48 and a 52-week high of $134.63.
Merck & Co., Inc. Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 8th. Shareholders of record on Monday, December 16th will be issued a $0.81 dividend. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.77. The ex-dividend date is Monday, December 16th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 3.28%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 67.92%.
Analyst Ratings Changes
MRK has been the topic of a number of recent analyst reports. Citigroup dropped their target price on shares of Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Sanford C. Bernstein began coverage on Merck & Co., Inc. in a report on Thursday, October 17th. They issued a “market perform” rating and a $115.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price target on shares of Merck & Co., Inc. in a research note on Thursday, October 3rd. Wolfe Research began coverage on Merck & Co., Inc. in a report on Friday, November 15th. They set a “peer perform” rating on the stock. Finally, Bank of America reaffirmed a “buy” rating and issued a $121.00 price objective on shares of Merck & Co., Inc. in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, nine have assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $126.57.
Check Out Our Latest Research Report on Merck & Co., Inc.
About Merck & Co., Inc.
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Further Reading
- Five stocks we like better than Merck & Co., Inc.
- Why Are Stock Sectors Important to Successful Investing?
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- What Are Treasury Bonds?
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- How to Plot Fibonacci Price Inflection Levels
- How Cigna Remains at the Top of the Health Insurance Food Chain
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.